872 related articles for article (PubMed ID: 29411879)
1. Understanding drug interactions with St John's wort (Hypericum perforatum L.): impact of hyperforin content.
Chrubasik-Hausmann S; Vlachojannis J; McLachlan AJ
J Pharm Pharmacol; 2019 Jan; 71(1):129-138. PubMed ID: 29411879
[TBL] [Abstract][Full Text] [Related]
2. Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line.
Tian R; Koyabu N; Morimoto S; Shoyama Y; Ohtani H; Sawada Y
Drug Metab Dispos; 2005 Apr; 33(4):547-54. PubMed ID: 15640377
[TBL] [Abstract][Full Text] [Related]
3. Hyperforin in St. John's wort drug interactions.
Madabushi R; Frank B; Drewelow B; Derendorf H; Butterweck V
Eur J Clin Pharmacol; 2006 Mar; 62(3):225-33. PubMed ID: 16477470
[TBL] [Abstract][Full Text] [Related]
4. Correlation of hyperforin content of Hypericum perforatum (St John's Wort) extracts with their effects on alcohol drinking in C57BL/6J mice: a preliminary study.
Wright CW; Gott M; Grayson B; Hanna M; Smith AG; Sunter A; Neill JC
J Psychopharmacol; 2003 Dec; 17(4):403-8. PubMed ID: 14870952
[TBL] [Abstract][Full Text] [Related]
5. Optimization of Light Intensity, Temperature, and Nutrients to Enhance the Bioactive Content of Hyperforin and Rutin in St. John's Wort.
Kuo CH; Chou YC; Liao KC; Shieh CJ; Deng TS
Molecules; 2020 Sep; 25(18):. PubMed ID: 32948004
[TBL] [Abstract][Full Text] [Related]
6. Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin.
Mueller SC; Uehleke B; Woehling H; Petzsch M; Majcher-Peszynska J; Hehl EM; Sievers H; Frank B; Riethling AK; Drewelow B
Clin Pharmacol Ther; 2004 Jun; 75(6):546-57. PubMed ID: 15179409
[TBL] [Abstract][Full Text] [Related]
7. The emerging recognition of herb-drug interactions with a focus on St. John's wort (Hypericum perforatum).
Markowitz JS; DeVane CL
Psychopharmacol Bull; 2001; 35(1):53-64. PubMed ID: 12397870
[TBL] [Abstract][Full Text] [Related]
8. Quantitative characterization of direct P-glycoprotein inhibition by St John's wort constituents hypericin and hyperforin.
Wang EJ; Barecki-Roach M; Johnson WW
J Pharm Pharmacol; 2004 Jan; 56(1):123-8. PubMed ID: 14980009
[TBL] [Abstract][Full Text] [Related]
9. Clinical risks of St John's Wort (Hypericum perforatum) co-administration.
Soleymani S; Bahramsoltani R; Rahimi R; Abdollahi M
Expert Opin Drug Metab Toxicol; 2017 Oct; 13(10):1047-1062. PubMed ID: 28885074
[TBL] [Abstract][Full Text] [Related]
10. Topical application of St John's wort (Hypericum perforatum L.) and of its metabolite hyperforin inhibits the allostimulatory capacity of epidermal cells.
Schempp CM; Winghofer B; Lüdtke R; Simon-Haarhaus B; Schöpf E; Simon JC
Br J Dermatol; 2000 May; 142(5):979-84. PubMed ID: 10809859
[TBL] [Abstract][Full Text] [Related]
11. Comparison of German St. John's wort products according to hyperforin and total hypericin content.
Wurglics M; Westerhoff K; Kaunzinger A; Wilke A; Baumeister A; Dressman J; Schubert-Zsilavecz M
J Am Pharm Assoc (Wash); 2001; 41(4):560-6. PubMed ID: 11486982
[TBL] [Abstract][Full Text] [Related]
12. Drug interactions with St John's wort : mechanisms and clinical implications.
Mannel M
Drug Saf; 2004; 27(11):773-97. PubMed ID: 15350151
[TBL] [Abstract][Full Text] [Related]
13. St. John's wort (Hypericum perforatum) and breastfeeding: plasma and breast milk concentrations of hyperforin for 5 mothers and 2 infants.
Klier CM; Schmid-Siegel B; Schäfer MR; Lenz G; Saria A; Lee A; Zernig G
J Clin Psychiatry; 2006 Feb; 67(2):305-9. PubMed ID: 16566628
[TBL] [Abstract][Full Text] [Related]
14. Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis.
Ng QX; Venkatanarayanan N; Ho CY
J Affect Disord; 2017 Mar; 210():211-221. PubMed ID: 28064110
[TBL] [Abstract][Full Text] [Related]
15. Current St John's wort research from mode of action to clinical efficacy.
Müller WE
Pharmacol Res; 2003 Feb; 47(2):101-9. PubMed ID: 12543057
[TBL] [Abstract][Full Text] [Related]
16. Modulation of P-glycoprotein function by St John's wort extract and its major constituents.
Weber CC; Kressmann S; Fricker G; Müller WE
Pharmacopsychiatry; 2004 Nov; 37(6):292-8. PubMed ID: 15551196
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic interactions of drugs with St John's wort.
Zhou S; Chan E; Pan SQ; Huang M; Lee EJ
J Psychopharmacol; 2004 Jun; 18(2):262-76. PubMed ID: 15260917
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the synaptosomal uptake inhibition of serotonin by St John's wort products.
Schulte-Löbbert S; Holoubek G; Müller WE; Schubert-Zsilavecz M; Wurglics M
J Pharm Pharmacol; 2004 Jun; 56(6):813-8. PubMed ID: 15231048
[TBL] [Abstract][Full Text] [Related]
19. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose.
Mueller SC; Majcher-Peszynska J; Uehleke B; Klammt S; Mundkowski RG; Miekisch W; Sievers H; Bauer S; Frank B; Kundt G; Drewelow B
Eur J Clin Pharmacol; 2006 Jan; 62(1):29-36. PubMed ID: 16341856
[TBL] [Abstract][Full Text] [Related]
20. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers.
Schulz HU; Schürer M; Bässler D; Weiser D
Arzneimittelforschung; 2005; 55(10):561-8. PubMed ID: 16294501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
